CA3157387A1 - Optimized gip peptide analogues - Google Patents

Optimized gip peptide analogues Download PDF

Info

Publication number
CA3157387A1
CA3157387A1 CA3157387A CA3157387A CA3157387A1 CA 3157387 A1 CA3157387 A1 CA 3157387A1 CA 3157387 A CA3157387 A CA 3157387A CA 3157387 A CA3157387 A CA 3157387A CA 3157387 A1 CA3157387 A1 CA 3157387A1
Authority
CA
Canada
Prior art keywords
gip
seq
amino acid
peptide analogue
cex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3157387A
Other languages
English (en)
French (fr)
Inventor
Mette Marie Rosenkilde
Alexander Hovard SPARRE-ULRICH
Ditte Riber
Samra Joke SANNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antag Therapeutics Aps
Original Assignee
Sanni Samra Joke
Sparre Ulrich Alexander Hovard
Antag Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by Sanni Samra Joke, Sparre Ulrich Alexander Hovard, Antag Therapeutics Aps filed Critical Sanni Samra Joke
Publication of CA3157387A1 publication Critical patent/CA3157387A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3157387A 2019-12-03 2020-12-03 Optimized gip peptide analogues Pending CA3157387A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EPPCT/EP2019/083506 2019-12-03
EP20179259.5 2020-06-10
EP20179259 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Publications (1)

Publication Number Publication Date
CA3157387A1 true CA3157387A1 (en) 2021-06-10

Family

ID=71083547

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3157387A Pending CA3157387A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Country Status (10)

Country Link
US (1) US20250346647A2 (enExample)
EP (1) EP4069719A1 (enExample)
JP (2) JP7788376B2 (enExample)
KR (1) KR20220108064A (enExample)
CN (1) CN114761420B (enExample)
AU (1) AU2020398675A1 (enExample)
CA (1) CA3157387A1 (enExample)
IL (1) IL293249A (enExample)
MX (1) MX2022006737A (enExample)
WO (1) WO2021110845A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139106A3 (en) * 2022-01-18 2023-09-07 Novo Nordisk A/S Long-acting gipr antagonists

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221661A1 (en) * 2021-06-10 2022-12-15 Alexander HOVARD SPARRE-ULRICH Treatment of obesity and obesity-related disorders
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
KR20070115947A (ko) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
WO2010016940A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN107129538B (zh) * 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
IN2014MN02304A (enExample) * 2012-05-03 2015-08-07 Zealand Pharma As
ES2685987T3 (es) * 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
KR102743887B1 (ko) * 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
SG11202105586YA (en) * 2018-12-03 2021-06-29 Antag Therapeutics Aps Modified gip peptide analogues

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139106A3 (en) * 2022-01-18 2023-09-07 Novo Nordisk A/S Long-acting gipr antagonists

Also Published As

Publication number Publication date
US20250346647A2 (en) 2025-11-13
MX2022006737A (es) 2022-06-14
EP4069719A1 (en) 2022-10-12
JP2023505441A (ja) 2023-02-09
JP2025172864A (ja) 2025-11-26
IL293249A (en) 2022-07-01
CN114761420B (zh) 2026-04-28
WO2021110845A1 (en) 2021-06-10
CN114761420A (zh) 2022-07-15
US20230416330A1 (en) 2023-12-28
JP7788376B2 (ja) 2025-12-18
KR20220108064A (ko) 2022-08-02
AU2020398675A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US12187773B2 (en) Modified GIP peptide analogues
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
JP6657230B2 (ja) インクレチン−インスリンコンジュゲート
US9764004B2 (en) Glucagon receptor agonists
JP7788376B2 (ja) 最適化されたｇｉｐペプチド類縁体
KR102824306B1 (ko) 인크레틴 유사체 및 그의 용도
CN111491658A (zh) 肠促胰岛素类似物及其用途
RS61107B1 (sr) Glukagon i glp-1 ko-agonist jedinjenja
CN101855240A (zh) 改进的胰岛淀粉样多肽衍生物
US11572399B2 (en) Long-acting GIP peptide analogues
JP2011525895A (ja) アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
RU2858286C2 (ru) Оптимизированные пептидные аналоги gip
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
EA043950B1 (ru) Аналоги инкретина и их применение

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250226

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTERNAL INVESTIGATION REQUEST

Effective date: 20260310